CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when JAK3 activity is inhibited.
Säemann
M D
MD
Institute of Immunology, Department of Internal Medicine III, University of Vienna, Borschkegasse 8A, 1080 Vienna, Austria.
Kelemen
P
P
Zeyda
M
M
Böhmig
G
G
Staffler
G
G
Zlabinger
G J
GJ
D015703:Antigens, CD / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000502:physiology*; D053616:Janus Kinase 3; D009000:Monocytes / Q000276:immunology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000494:pharmacology*
D015703:Antigens, CD; D019013:CD40 Antigens; D004791:Enzyme Inhibitors; D011799:Quinazolines; C113888:WHI P154; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; D053616:Janus Kinase 3